22090-24-0

Basic information

• Product Name: 4-PIPERIDIN-1-YL-BENZOIC ACID
• Synonyms: 4-PIPERIDIN-1-YL-BENZOIC ACID;4-PIPERIDINOBENZOIC ACID;AKOS B022044;CHEMBRDG-BB 4400214;BUTTPARK 99\50-11;ART-CHEM-BB B022044;OTAVA-BB BB5300270010;TIMTEC-BB SBB007144
• CAS NO: 22090-24-0
• Molecular Formula: C₁₂H₁₅NO₂
• Molecular Weight: 205.25
• Mol File: 22090-24-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 222-224 °C(Solv: benzene (71-43-2))
• Boiling Point: 388.9 °C at 760 mmHg
• Flash Point: 189 °C
• Appearance: /
• Density: 1.178 g/cm³
• Vapor Pressure: 9.56E-07mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.65±0.10(Predicted)
• CAS DataBase Reference: 4-PIPERIDIN-1-YL-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERIDIN-1-YL-BENZOIC ACID(22090-24-0)
• EPA Substance Registry System: 4-PIPERIDIN-1-YL-BENZOIC ACID(22090-24-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 22090-24-0(Hazardous Substances Data)

Usage

General Description

4-PIPERIDIN-1-YL-BENZOIC ACID, also known as piperidinylbenzoic acid, is a chemical compound that belongs to the family of benzoic acids and piperidines. It has a molecular formula of C14H17NO2 and a molecular weight of 231.29 g/mol. 4-PIPERIDIN-1-YL-BENZOIC ACID is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs, particularly as a precursor in the production of psychiatric medications and antihistamines. It is also known for its potential anti-inflammatory and analgesic properties, making it a promising candidate for the development of new therapeutic agents. Additionally, 4-PIPERIDIN-1-YL-BENZOIC ACID is used in the research and development of organic compounds and materials due to its versatile chemical reactivity and structural features.

InChI:InChI=1/C12H15NO2/c14-12(15)10-4-6-11(7-5-10)13-8-2-1-3-9-13/h4-7H,1-3,8-9H2,(H,14,15)/p-1

Upstream product

• 1204-85-9 4-(piperidin-1-yl)benzonitrile 
• 111-24-0 1,5-dibromo-pentane 
• 150-13-0 4-amino-benzoic acid 
• 110-89-4 piperidine 
• 456-22-4 4-Fluorobenzoic acid 
• 1194-02-1 4-fluorobenzonitrile 
• 623-00-7 4-bromobenzenecarbonitrile 
• 101038-65-7 ethyl 4-(piperidine-1-yl)benzoate 
• 10338-58-6 N-(4-[methyl 4-benzoxycarbonyl])piperidine 
• 10342-85-5 4-piperidinoacetophenone 
• 1171309-72-0 2-oxo-2-[4-(1-piperidinyl)phenyl]acetaldehyde monohydrate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 10338-57-5 4-(piperidin-1-yl)benzaldehyde 

Downstream Products

• 106947-67-5 4-(1-Oxy-piperidin-1-yl)-benzoic acid 
• 221360-47-0 (S)-N-[5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-piperidinobenzamide 
• 151296-46-7 4-Piperidinobenzoylguanidine hydrochloride 
• 1140460-77-0 1-(4-{3-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}phenyl)piperidine 
• 1159096-70-4 C₂₄H₂₈N₄O 
• 1616961-20-6 N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-(piperidin-1-yl)benzamide 
• 1616960-78-1 N-(2-(2-methyl-1H-indol-1-yl)ethyl)-4-(piperidin-1-yl)benzamide 
• 10338-58-6 N-(4-[methyl 4-benzoxycarbonyl])piperidine 

Relevant articles and documents

Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified ～100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further ～90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.

COMPOUNDS FOR TREATING VIRAL INFECTIONS

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

OXADIAZOLE DIARYL COMPOUNDS

The invention relates to compounds of formula (I): wherein R1, R2, Ra , Rb,Rc and W, have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.